Cargando…

Myelofibrosis in 2019: moving beyond JAK2 inhibition

Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by ineffective clonal hematopoiesis, splenomegaly, bone marrow fibrosis, and the propensity for transformation to acute myeloid leukemia. The discovery of mutations in JAK2, CALR, and MPL have uncovered activated JAK-STAT signaling as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schieber, Michael, Crispino, John D., Stein, Brady
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6739355/ https://www.ncbi.nlm.nih.gov/pubmed/31511492 http://dx.doi.org/10.1038/s41408-019-0236-2

Ejemplares similares

JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives
por: Bose, Prithviraj, et al.
Publicado: (2020)

Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis
por: Tefferi, Ayalew, et al.
Publicado: (2023)

Treatment and management of myelofibrosis in the era of JAK inhibitors
por: Keohane, Clodagh, et al.
Publicado: (2013)

Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape
por: Tefferi, Ayalew, et al.
Publicado: (2022)

The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes
por: Mascarenhas, John O., et al.
Publicado: (2022)

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
por: Pardanani, A, et al.
Publicado: (2013)

Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis
por: Kuykendall, Andrew T., et al.
Publicado: (2020)

Will JAK1/2 inhibitors change the standard of care for myelofibrosis?
por: Jung, Chul Won
Publicado: (2012)

The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis
por: Barone, Martina, et al.
Publicado: (2020)

Germline-somatic JAK2 interactions are associated with clonal expansion in myelofibrosis
por: Brown, Derek W., et al.
Publicado: (2022)

The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation
por: Ikeda, Kazuhiko, et al.
Publicado: (2017)

Treatment and management of myelofibrosis in the era of JAK inhibitors [Corrigendum]
Publicado: (2013)

Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor
por: Tremblay, Douglas, et al.
Publicado: (2023)

Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis
por: Tvorogov, Denis, et al.
Publicado: (2018)

Advancing brain-machine interfaces: moving beyond linear state space models
por: Rouse, Adam G., et al.
Publicado: (2015)

Cutaneous cryptococcosis in a patient with myelofibrosis receiving JAK‐inhibitor
por: Chen, Jui‐Che, et al.
Publicado: (2021)

Moving beyond Titers
por: Brooks, Benjamin D., et al.
Publicado: (2022)

Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis
por: Brattås, Marte Karen, et al.
Publicado: (2018)

Development of JAK2 positive myelofibrosis on a background of chronic myeloid leukaemia
por: Mullen, Christopher Gerard, et al.
Publicado: (2022)

Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2019)

Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia
por: dos Santos, Leonardo Caires, et al.
Publicado: (2011)

Many questions raised by a question on JAK1/2 inhibitors in primary myelofibrosis
por: Raut, Lalit
Publicado: (2013)

Inhibition of Osteoblast Differentiation by JAK2(V617F) Megakaryocytes Derived From Male Mice With Primary Myelofibrosis
por: Karagianni, Aikaterini, et al.
Publicado: (2022)

A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis
por: Verstovsek, S, et al.
Publicado: (2017)

Coexisting BRAF-Mutated Langerhans Cell Histiocytosis and Primary Myelofibrosis with Shared JAK2 Mutation
por: Holst, Johanne Marie, et al.
Publicado: (2021)

The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review
por: Tiribelli, Mario, et al.
Publicado: (2019)

Inhibition of interleukin-1β reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm
por: Rai, Shivam, et al.
Publicado: (2022)

A Rare Co-Occurrence of Triple Mutations in JAK2, CALR, and MPL in the Same Patient with Myelofibrosis
por: Thomas, Sherine J., et al.
Publicado: (2022)

Loss of wild-type Jak2 allele enhances myeloid cell expansion and accelerates myelofibrosis in Jak2V617F knock-in mice
por: Akada, Hajime, et al.
Publicado: (2014)

Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis
por: Shimizu, Takafumi, et al.
Publicado: (2016)

Moving beyond Inclusion to Belonging
por: Long, Toby, et al.
Publicado: (2023)

HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis
por: Sevin, Margaux, et al.
Publicado: (2018)

State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019
por: McLornan, Donal P., et al.
Publicado: (2019)

JAK2 V617F Genotype Is a Strong Determinant of Blast Transformation in Primary Myelofibrosis
por: Barosi, Giovanni, et al.
Publicado: (2013)

Basic Mechanisms of JAK Inhibition
por: Lin, Chung MA, et al.
Publicado: (2020)

P987: IRAK1 AND JAK2 DUAL INHIBITION WITH PACRITINIB PREVENTS MYELOFIBROSIS-LIKE PHENOTYPE IN AN INFLAMMATION-DRIVEN MURINE MODEL
por: Zamora, Ernesto José Cuenca, et al.
Publicado: (2023)

JAK2 Exon 14 Skipping in Patients with Primary Myelofibrosis: A Minor Splice Variant Modulated by the JAK2-V617F Allele Burden
por: Catarsi, Paolo, et al.
Publicado: (2015)

Nephrotic syndrome in primary myelofibrosis with renal extramedullary hematopoiesis and glomerulopathy in the JAK inhibitor era
por: Del Sordo, Rachele, et al.
Publicado: (2017)

Cancer immunotherapy: Moving beyond checkpoint inhibition
por: Boes, Marianne
Publicado: (2018)

Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis
por: Jamieson, Catriona, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1gbdf0dit59k5mo12ulpleqffn